Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 6Thoracic 5Lymphoid 3Genitourinary 3CNS 3Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2

Conditions

Meningioma 2Neurofibromatosis 2 1Glioblastoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × vistusertib × CNS × Clear all
NCT02619864 2023-08-04

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Canadian Cancer Trials Group

Phase 1 Completed
15 enrolled
CNS

Glioblastoma

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown
28 enrolled
CNS

Meningioma

NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡